Table 2.
Evaluated Parameters at Consecutive Follow-Up Visits (n=32)
| Variable | Baseline | Day 1 | Day 7 | Month 1 | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|---|---|---|
| Eyes, n | 32 | 23 | 32 | 32 | 32 | 32 | 5 |
| Lost during follow-up, % | 0 | 31.2 | 0 | 0 | 0 | 0 | 84.3 |
IOP (mm Hg),  ± SD |
15.9 ±3.6 | 17.4 ±10.4 | 15.5 ±8.3 | 13.2 ±3.3 | 12.6 ±1.6 | 12.5 ±1.4 | 12.0 ±1.6 |
| IOP (mm Hg), median (IQR) | 15 (13.2–18) | 15 (10–22) | 13 (11–16.7) | 12 (12–15) | 12 (12–14) | 13 (11–14) | 12 (10–13) |
| IOP reduction,% | NA | 8 | 3 | 13.3 | 18.1 | 18.6 | 21.8 |
| Eyes with a >20% IOP reduction, % | NA | 47.8 | 43.7 | 50 | 46.8 | 43.7 | 60 |
| Percentage of complete success, % | NA | NA | NA | 56.2 | 68.7 | 65.6 | – |
Number of glaucoma medications,  ± SD |
1.8 ±1.4 | NA | NA | 0.46 ±1 | 0.65 ±1 | 0.59 ±1 | – |
| Number of glaucoma medications, median (IQR) | 2 (0.25–3) | 0 (0–0) | 0 (0–1) | 0 (0–1) |
Abbreviations:
, mean; SD, standard deviation; IOP, intraocular pressure; IQR, interquartile range; NA, no applicable.